UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.
A group of activists has been campaigning to bar UBS from the U.S. pension market given the "serious financial crimes" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback